Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Recordati Industria Chimica e Farmaceutica SPA reported strong financial growth in the first nine months of 2024, with revenues rising by 12% to €1,743.1 million and EBITDA increasing by 11.8% to €665.7 million. The company’s performance was bolstered by robust gains in both the Specialty & Primary Care and Rare Diseases sectors, while strategic agreements like the acquisition of Enjaymo® from Sanofi further bolster its market position. Recordati also announced a new stock buyback program, highlighting its commitment to enhancing shareholder value.
For further insights into IT:REC stock, check out TipRanks’ Stock Analysis page.
